FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2740888944> ?p ?o ?g. }

• W2740888944 endingPage "38" @default.
• W2740888944 startingPage "29" @default.
• W2740888944 abstract "As part of its single technology appraisal process, the National Institute for Health and Care Excellence invited the manufacturer of pertuzumab (Perjeta®; Roche Products Limited) to submit evidence of its clinical and cost- effectiveness for the neoadjuvant treatment of women with high-risk, early-stage, HER2-positive breast cancer when used in combination with trastuzumab and chemotherapy. High-risk women included those with locally advanced (including inflammatory) breast cancer and women with high-risk early-stage breast cancer (classified as T2/3 or N1). The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group. This article presents the critical review of the company's submission by the Evidence Review Group and the outcome of the National Institute for Health and Care Excellence guidance. The clinical data were mainly taken from a phase II, randomised, open-label, active controlled study (NeoSphere), which reported a significant advantage in terms of pathological complete response rates of pertuzumab in combination with trastuzumab and chemotherapy, compared with trastuzumab alone with chemotherapy (45.8 vs. 29.0%, p = 0.0141). The company did not make any indirect comparisons. A meta-analysis of 12 neoadjuvant studies investigating the relationship between pathological complete response and event-free survival was used to extrapolate the outcomes reported in the NeoSphere study. A cardiac safety study (TRYPHAENA) demonstrated the safety of pertuzumab. The company undertook a model-based economic evaluation of neoadjuvant pertuzumab plus trastuzumab and docetaxel compared with neoadjuvant trastuzumab and docetaxel over a lifetime horizon from the National Health Service and Personal Social Services perspective. The probabilistic incremental cost-effectiveness ratio was estimated to be £20,104 per quality-adjusted life-year gained for pertuzumab alongside trastuzumab and docetaxel compared with trastuzumab and docetaxel, which was revised to £21,869 per quality-adjusted life-year gained following the clarification process. The Evidence Review Group corrected an error in the digitisation of the survivor functions and modified the clinically inappropriate assumption that recurrence is zero after 7 years. The Evidence Review Group's probabilistic base case was £23,962 per quality-adjusted life-year gained. During the appraisal, to mitigate the uncertainties associated with the evidence, the company offered a patient access scheme, which led to the National Institute for Health and Care Excellence Appraisal Committee recommending pertuzumab in this patient group, subject to the company providing the agreed discount in the patient access scheme." @default.
• W2740888944 created "2017-08-08" @default.
• W2740888944 creator A5024646520 @default.
• W2740888944 creator A5044011427 @default.
• W2740888944 creator A5046488246 @default.
• W2740888944 creator A5051652828 @default.
• W2740888944 creator A5051980635 @default.
• W2740888944 creator A5058853190 @default.
• W2740888944 creator A5064175110 @default.
• W2740888944 creator A5070119593 @default.
• W2740888944 date "2017-08-02" @default.
• W2740888944 modified "2023-09-27" @default.
• W2740888944 title "Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal" @default.
• W2740888944 cites W1982967337 @default.
• W2740888944 cites W1996778928 @default.
• W2740888944 cites W2020677481 @default.
• W2740888944 cites W2048059530 @default.
• W2740888944 cites W2052592826 @default.
• W2740888944 cites W2075894019 @default.
• W2740888944 cites W2095861620 @default.
• W2740888944 cites W2096620495 @default.
• W2740888944 cites W2123591186 @default.
• W2740888944 cites W2283816551 @default.
• W2740888944 doi "https://doi.org/10.1007/s40273-017-0556-7" @default.
• W2740888944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28770452" @default.
• W2740888944 hasPublicationYear "2017" @default.
• W2740888944 type Work @default.
• W2740888944 sameAs 2740888944 @default.
• W2740888944 citedByCount "12" @default.
• W2740888944 countsByYear W27408889442018 @default.
• W2740888944 countsByYear W27408889442019 @default.
• W2740888944 countsByYear W27408889442020 @default.
• W2740888944 countsByYear W27408889442021 @default.
• W2740888944 countsByYear W27408889442022 @default.
• W2740888944 crossrefType "journal-article" @default.
• W2740888944 hasAuthorship W2740888944A5024646520 @default.
• W2740888944 hasAuthorship W2740888944A5044011427 @default.
• W2740888944 hasAuthorship W2740888944A5046488246 @default.
• W2740888944 hasAuthorship W2740888944A5051652828 @default.
• W2740888944 hasAuthorship W2740888944A5051980635 @default.
• W2740888944 hasAuthorship W2740888944A5058853190 @default.
• W2740888944 hasAuthorship W2740888944A5064175110 @default.
• W2740888944 hasAuthorship W2740888944A5070119593 @default.
• W2740888944 hasBestOaLocation W27408889442 @default.
• W2740888944 hasConcept C121608353 @default.
• W2740888944 hasConcept C126322002 @default.
• W2740888944 hasConcept C143998085 @default.
• W2740888944 hasConcept C2779786085 @default.
• W2740888944 hasConcept C2781164504 @default.
• W2740888944 hasConcept C2781190966 @default.
• W2740888944 hasConcept C530470458 @default.
• W2740888944 hasConcept C71924100 @default.
• W2740888944 hasConceptScore W2740888944C121608353 @default.
• W2740888944 hasConceptScore W2740888944C126322002 @default.
• W2740888944 hasConceptScore W2740888944C143998085 @default.
• W2740888944 hasConceptScore W2740888944C2779786085 @default.
• W2740888944 hasConceptScore W2740888944C2781164504 @default.
• W2740888944 hasConceptScore W2740888944C2781190966 @default.
• W2740888944 hasConceptScore W2740888944C530470458 @default.
• W2740888944 hasConceptScore W2740888944C71924100 @default.
• W2740888944 hasFunder F4320334661 @default.
• W2740888944 hasIssue "1" @default.
• W2740888944 hasLocation W27408889441 @default.
• W2740888944 hasLocation W27408889442 @default.
• W2740888944 hasLocation W27408889443 @default.
• W2740888944 hasOpenAccess W2740888944 @default.
• W2740888944 hasPrimaryLocation W27408889441 @default.
• W2740888944 hasRelatedWork W2343994751 @default.
• W2740888944 hasRelatedWork W2540085961 @default.
• W2740888944 hasRelatedWork W2544874841 @default.
• W2740888944 hasRelatedWork W2587365770 @default.
• W2740888944 hasRelatedWork W2900007630 @default.
• W2740888944 hasRelatedWork W2977564111 @default.
• W2740888944 hasRelatedWork W3031648518 @default.
• W2740888944 hasRelatedWork W3199640643 @default.
• W2740888944 hasRelatedWork W4239851800 @default.
• W2740888944 hasRelatedWork W4286512930 @default.
• W2740888944 hasVolume "36" @default.
• W2740888944 isParatext "false" @default.
• W2740888944 isRetracted "false" @default.
• W2740888944 magId "2740888944" @default.
• W2740888944 workType "article" @default.